Combination of Durvalumab and Tremelimumab May Prolong OS in CRC
This phase II trial suggested that combination immune checkpoint inhibition with durvalumab plus tremelimumab may be associated with prolonged overall survival in patients with advanced refractory colorectal cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Hannah Slater Source Type: news